Michael R Lassen

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
    M R Lassen
    Department of Orthopaedics and Clinical Trial Unit, Nordsjaellands Hospital Hoersholm, University of Copenhagen, Usseroed Kongevej 102, Hoersholm, Denmark
    J Thromb Haemost 5:2368-75. 2007
  2. ncbi Emergence of new oral antithrombotics: a critical appraisal of their clinical potential
    Michael Rud Lassen
    Department of Orthopaedics and Clinical Trial Unit, Nordsjaellands Hospital Hørsholm, University of Copenhagen, Usserød Kongevej 102, Hørsholm, Denmark
    Vasc Health Risk Manag 4:1373-86. 2008
  3. ncbi SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study
    Michael R Lassen
    Hørsholm Hospital, Hørsholm, Denmark
    J Am Coll Cardiol 51:1498-504. 2008
  4. ncbi Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    Michael R Lassen
    Nordsjaellands Hospital, Hørsholm, Denmark
    N Engl J Med 358:2776-86. 2008
  5. ncbi AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study
    M R Lassen
    Hørsholm Hospital, Spine Clinic, Hørsholm, Denmark
    J Thromb Haemost 7:566-72. 2009
  6. ncbi Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
    Michael Rud Lassen
    Department of Orthopedics, Spine Clinic, and Clinical Trial Unit, Hørsholm Hospital, University of Copenhagen, Hørsholm, Denmark
    N Engl J Med 363:2487-98. 2010
  7. ncbi Recent developments in the use of oral anticoagulants
    Michael R Lassen
    Hørsholm Hospital, Department of Orthopedic Surgery, Usserød Kongevej 102, DK 2970, Hørsholm, Denmark
    Expert Opin Pharmacother 10:1769-81. 2009
  8. ncbi Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
    Michael Rud Lassen
    Department of Orthopaedics, Spine Clinic, Clinical Trial Unit, Hørsholm Hospital, University of Copenhagen, Hørsholm, Denmark
    Lancet 375:807-15. 2010
  9. ncbi Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization
    Michael R Lassen
    Department of Orthopedics, Hillerød Hospital, Hillerød, Denmark
    N Engl J Med 347:726-30. 2002
  10. ncbi Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement
    Lars C Borris
    Department of Orthopaedics, Arhus University Hospital, Nørrebrogade 44, 8000 Arhus C, Denmark
    Thrombosis 2011:150750. 2011

Detail Information

Publications10

  1. ncbi The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
    M R Lassen
    Department of Orthopaedics and Clinical Trial Unit, Nordsjaellands Hospital Hoersholm, University of Copenhagen, Usseroed Kongevej 102, Hoersholm, Denmark
    J Thromb Haemost 5:2368-75. 2007
    ..Heparins and warfarin are currently used as venous thromboembolism (VTE) prophylaxis in surgery. Inhibition of factor (F) Xa provides a specific mechanism of anticoagulation and the potential for an improved benefit-risk profile...
  2. ncbi Emergence of new oral antithrombotics: a critical appraisal of their clinical potential
    Michael Rud Lassen
    Department of Orthopaedics and Clinical Trial Unit, Nordsjaellands Hospital Hørsholm, University of Copenhagen, Usserød Kongevej 102, Hørsholm, Denmark
    Vasc Health Risk Manag 4:1373-86. 2008
    ..In addition, the impact that the introduction of such agents into clinical practice would have is discussed from the patient perspective...
  3. ncbi SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study
    Michael R Lassen
    Hørsholm Hospital, Hørsholm, Denmark
    J Am Coll Cardiol 51:1498-504. 2008
    ..This study assessed the dose response of SR123781A for the prevention of venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) surgery...
  4. ncbi Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    Michael R Lassen
    Nordsjaellands Hospital, Hørsholm, Denmark
    N Engl J Med 358:2776-86. 2008
    ..We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty...
  5. ncbi AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study
    M R Lassen
    Hørsholm Hospital, Spine Clinic, Hørsholm, Denmark
    J Thromb Haemost 7:566-72. 2009
    ..AVE5026 is in clinical development for venous thromboembolism (VTE) prevention, a frequent complication after total knee replacement (TKR) surgery...
  6. ncbi Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
    Michael Rud Lassen
    Department of Orthopedics, Spine Clinic, and Clinical Trial Unit, Hørsholm Hospital, University of Copenhagen, Hørsholm, Denmark
    N Engl J Med 363:2487-98. 2010
    ..Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use...
  7. ncbi Recent developments in the use of oral anticoagulants
    Michael R Lassen
    Hørsholm Hospital, Department of Orthopedic Surgery, Usserød Kongevej 102, DK 2970, Hørsholm, Denmark
    Expert Opin Pharmacother 10:1769-81. 2009
    ..Additionally, these drugs show potential for stroke prevention in atrial fibrillation, treatment of venous thromboembolism and prevention of secondary events in acute coronary syndrome...
  8. ncbi Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
    Michael Rud Lassen
    Department of Orthopaedics, Spine Clinic, Clinical Trial Unit, Hørsholm Hospital, University of Copenhagen, Hørsholm, Denmark
    Lancet 375:807-15. 2010
    ..Apixaban, an orally active factor Xa inhibitor, might be as effective, have lower bleeding risk, and be easier to use than is enoxaparin. We assessed efficacy and safety of these drugs after elective total knee replacement...
  9. ncbi Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization
    Michael R Lassen
    Department of Orthopedics, Hillerød Hospital, Hillerød, Denmark
    N Engl J Med 347:726-30. 2002
    ..Deep-vein thrombosis is a well-recognized complication after trauma to the legs and subsequent immobilization, but there are no generally accepted approaches to preventing this complication...
  10. ncbi Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement
    Lars C Borris
    Department of Orthopaedics, Arhus University Hospital, Nørrebrogade 44, 8000 Arhus C, Denmark
    Thrombosis 2011:150750. 2011
    ..Measurement of uF1+2 could provide a simple, non-invasive clinical test to identify patients at risk of VTE...